MedTrace Logo

Anti-Inflammatory Agent in Sinusitis

NCT02874144 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2022-05-25

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy of an anti-inflammatory agent compared with placebo in relieving signs and symptoms of disease in patients with sinusitis.

Conditions

  • Nasal Polyps

Interventions

DRUG

AZ compound

40 mg three times daily po for 12 weeks

OTHER

Collection of Biological Specimens

collection of biomarkers for analysis of nasal disease

DRUG

Intranasal corticosteroid

QD Nasal Spray

DRUG

Placebo

looks like AZ compound, made by same company, double blind. 40 mg three times daily po for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Anju T Peters, MD · Northwestern University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-20
Primary Completion
2020-01-07
Completion
2020-08-10

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02874144 on ClinicalTrials.gov